Biosciences Company Tempus Brings In $130 Million
Tempus announced the completion of $130 million in Series C financing led by New Enterprise Associates and Revolution Growth.
Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It also provides genomic sequencing services and analyzes molecular and therapeutic data to empower physicians to make real-time, data-driven decisions.